Audited annual report 2024 of AS Pro Kapital Grupp The Supervisory Board of AS Pro Kapital Grupp has approved the Group’s audited annual report for 2024. In 2024, AS Pro Kapital Grupp (hereafter referred to as the Group) revenue amounted to 18.2 million euros, representing a decrease of 4.9 million euros compared to the previous financial year. The decrease in revenue resulted from lower sales volumes, as most of the available units had already been sold, and the Group’s main focus in 2024 remained on the c ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/actinium-law ...

CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, which supports the rational molecular design of zidesamtinib, its novel and selective ROS1 inhibitor. Zidesamtinib is currently being evaluated in the ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fluence Energy, Inc. ("Fluence Energy" or the "Company") (NASDAQ: FLNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fluence Energy investors who were adversely affected by alleged securities fraud between October 28, 2021 and February 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/fluen ...

Core Insights - The company reported a strong performance in Q1 2025, with sales of goods and services reaching ISK 37,786 million, a year-on-year increase of 17.3% [4] - Profit for the quarter amounted to ISK 279 million, reflecting a 35.2% increase from the previous year [4] - The EBITDA guidance for the year 2025 remains unchanged at ISK 14,400 – 14,800 million [4] Financial Performance - Sales of goods and services increased by 17.3% year-on-year, with a 3.0% increase when excluding the impact of Lyfja [4] - The profit margin improved to 24.4%, up by 2.6 percentage points from Q1 2024 [4] - Operating expenses rose by 28.9% year-on-year, while the number of full-time equivalents increased by 281 [4] Strategic Developments - The company plans to open a new store in Reykjanesbær and close a smaller store in the same area [4] - An acquisition of property in Hafnarfjörður was made to secure key locations for future development [4] - New fuel pumps will be opened at Fiskislóð, with closures at Ægissíða as part of an agreement with the City of Reykjavík [4] Market Outlook - The company anticipates a good outlook for the summer season, which is critical for its operations [6] - Despite uncertainties in global markets due to tariff increases and policy changes, management believes the impact on operations will be minimal [6] - The company emphasizes strong foundations and technical infrastructure, indicating confidence in navigating market challenges [6]

CyberArk (CYBR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual investors oft ...

GeneDx Holdings Corp. (WGS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...

Alignment Healthcare (ALHC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The ...

Middlefield Banc Corp. (MBCN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Ind ...

Astellas Pharma Inc. (ALPMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ye ...